Supernus Q2 total revenues down 20% to $135.5M; Qelbree sales up 179%

SUPERNUS PHARMACEUTICALS, INC.

2023-Q2 EPS reported $0.29 revenue$289,327,000

GAAP operating loss of $17.6M vs income of $11.3M in Q2 2022; net loss $0.8M ($0.02 loss per share).
Qelbree net sales $31.0M (+179% YoY), GOCOVRI $28.8M (+17%); Trokendi XR fell 73% to $19.3M on generic erosion.
Non-GAAP adjusted operating earnings of $10.0M in Q2 vs $37.6M a year ago; six-month adjusted earnings $40.5M.
Full-year 2023 guidance reaffirmed: revenues $580–620M, GAAP operating loss ($30)–($10)M, non-GAAP op earnings $75–100M.
Cash and marketable securities $189.1M at June 30; completed $402.5M convertible note and $93M credit line repayments.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

SUPERNUS PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $135.5 million.

Period: the second quarter ended June 30, 2023
Revenue: $135.5 million
Result: reported results

Exact text from the filing

expects to have data in the first half of 2024. Financial Highlights Total revenues For the three months ended June 30, 2023, total revenues and total net product sales were $135.5 million and $128.3 million, respectively, compared to total revenues and total net product sales of $170.1 million and $165.5 million for the same periods in 2022. For the six months

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

SUPERNUS PHARMACEUTICALS, INC. reported the first six months of 2023 results: revenue $289.3 million.

Period: the first six months of 2023
Revenue: $289.3 million
Result: reported results

Exact text from the filing

Total revenues of $289.3 million in the first six months of 2023

View on SEC.gov

Browse all earnings releases →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-23-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.